3 Years Ago
1 Min Read
ROIV down -6%. Here's what's moving the stock:
Shares of Roivant Sciences Ltd (ROIV) are trading -6% lower at a price of $3.73 at the time of this writing.
- The CEO of Roivant Sciences, Matt Gline, said that they are ending development of their top lentiviral gene therapy for sickle cell disease and β-thalassemia due to future development costs and current market conditions.
- ROIV is axing gene therapy and dermatology candidates from their development pipeline due to similar reasons.
- ROIV has teamed up with Pfizer to launch Priovant Therapeutics, which is focused on developing novel therapies for autoimmune diseases.
Roivant Sciences Ltd has been trading between a 52-week high of $16.76 and a 52-week low of $2.52. The stock has a market cap of $2.62 Billion.
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies
Headlines
Roivant Sciences Ltd. (ROIV) CEO Matt Gline on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 06-28-22
Roivant Sciences Ltd. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:ROIV)
Seeking Alpha 06-28-22
Roivant axes gene therapy, dermatology and excessive sweating candidates from development
Seeking Alpha 06-28-22
Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases
Benzinga 06-28-22
Roivant Sciences teams up with Pfizer to launch Priovant (NASDAQ:ROIV)
Seeking Alpha 06-28-22
Recommended Articles
